TikTok seeks to reassure U.S. employees ahead of Jan. 19 ban deadline
US won't seek charges in unarmed Black motorist Ronald Greene's fatal 2019 arrest
Euro zone households could increase consumption, ECB chief economist says
Foreigners sold South Korean equities last month by most since early 2020
Trump and Biden national and homeland security staff will meet Wednesday for threat exercises
As fires ravage Los Angeles, Tiger Woods isn't sure what will happen with Riviera tournament
Antetokounmpo gets 50th career triple-double as Bucks win 130-115 to end Kings' 7-game win streak
No 97 Laura Siegemund upsets Olympic champion Zheng Qinwen at the Australian Open
(Reuters) - Pfizer Inc on Friday cut forecast for 2023 revenue to between $58 billion and $61 billion, from $67 billion to $70 billion previously.
Shares of the company were down about 7% in extended trading.
The company also reduced its outlook for Paxlovid revenues by about $7 billion. It had previously expected Paxlovid revenues of about $8 billion.
Pfizer added the U.S. government will be returning an estimated 7.9 million doses of Paxlovid at the end of this year. (This story has been corrected to say that the revenue outlook for Paxlovid was reduced by $7 billion, not to $7 billion, in paragraph 3)
(Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
